BridgeBio Pharma (BBIO) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
221.9M
Gross Profit
218.0M
98.25%
Operating Income
-577.4M
-260.19%
Net Income
-543.3M
-244.86%
EPS (Diluted)
-$2.88
Balance Sheet Metrics
Total Assets
919.3M
Total Liabilities
2.4B
Shareholders Equity
-1.5B
Cash Flow Metrics
Operating Cash Flow
-408.3M
Free Cash Flow
-529.6M
Revenue & Profitability Trend
BridgeBio Pharma Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 221.9M | 9.3M | 77.6M | 69.7M | 8.2M |
| Cost of Goods Sold | 3.9M | 2.4M | 3.4M | 3.1M | 0 |
| Gross Profit | 218.0M | 6.9M | 74.2M | 66.6M | 8.2M |
| Operating Expenses | 795.4M | 606.3M | 542.7M | 643.2M | 482.7M |
| Operating Income | -577.4M | -599.4M | -468.4M | -576.6M | -474.5M |
| Pre-tax Income | -542.2M | -653.3M | -484.7M | -586.5M | -505.5M |
| Income Tax | 1.2M | - | - | - | - |
| Net Income | -543.3M | -653.3M | -484.7M | -586.5M | -505.5M |
| EPS (Diluted) | -$2.88 | -$3.95 | -$3.26 | -$3.90 | -$3.80 |
Income Statement Trend
BridgeBio Pharma Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 720.7M | 477.6M | 548.9M | 888.9M | 642.8M |
| Non-Current Assets | 198.6M | 68.8M | 74.2M | 123.9M | 60.8M |
| Total Assets | 919.3M | 546.4M | 623.0M | 1.0B | 703.6M |
| Liabilities | |||||
| Current Liabilities | 154.4M | 143.8M | 121.4M | 135.1M | 95.6M |
| Non-Current Liabilities | 2.2B | 1.7B | 1.7B | 1.7B | 500.1M |
| Total Liabilities | 2.4B | 1.9B | 1.9B | 1.9B | 595.7M |
| Equity | |||||
| Total Shareholders Equity | -1.5B | -1.3B | -1.2B | -865.6M | 107.9M |
Balance Sheet Composition
BridgeBio Pharma Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -543.3M | -653.3M | -484.7M | -586.5M | -505.5M |
| Operating Cash Flow | -408.3M | -508.4M | -441.5M | -488.1M | -407.7M |
| Investing Activities | |||||
| Capital Expenditures | -933.0K | -1.3M | -4.8M | -13.2M | -7.5M |
| Investing Cash Flow | 43.1M | 54.0M | 454.6M | -165.8M | -53.0M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | 0 |
| Financing Cash Flow | 740.3M | 442.1M | -16.4M | 777.3M | 482.3M |
| Free Cash Flow | -529.6M | -529.0M | -425.8M | -546.2M | -407.2M |
Cash Flow Trend
BridgeBio Pharma Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-14.78
Forward P/E
-13.78
Price to Sales
62.85
PEG Ratio
-13.78
Profitability Ratios
Profit Margin
98.25%
Operating Margin
-89.00%
Return on Equity
36.76%
Return on Assets
-48.27%
Financial Health
Current Ratio
4.57
Debt to Equity
-1.13
Beta
1.10
Per Share Data
EPS (TTM)
-$3.56
Book Value per Share
-$8.68
Revenue per Share
$0.67
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| bbio | 8.0B | -14.78 | - | 36.76% | 98.25% | -1.13 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Blueprint Medicines | 8.3B | -120.00 | 24.19 | -47.71% | -27.70% | 208.50 |
| Roivant Sciences | 7.8B | 1.95 | 1.71 | -12.54% | 96.86% | 1.93 |
| Bio-Techne | 7.9B | 60.87 | 3.92 | 6.53% | 10.89% | 20.99 |
Financial data is updated regularly. All figures are in the company's reporting currency.